Edition:
United States

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

17.39USD
3:59pm EST
Change (% chg)

$-0.32 (-1.81%)
Prev Close
$17.71
Open
$17.71
Day's High
$18.23
Day's Low
$17.31
Volume
305,273
Avg. Vol
210,599
52-wk High
$33.20
52-wk Low
$10.83

Chart for

About

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that... (more)

Overall

Beta: --
Market Cap(Mil.): $1,116.97
Shares Outstanding(Mil.): 36.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share

* Intellia Therapeutics announces pricing of public offering of common stock

Nov 01 2017

BRIEF-Intellia Therapeutics announces proposed public offering of common stock

* Intellia therapeutics announces proposed public offering of common stock

Nov 01 2017

BRIEF-Intellia Therapeutics Q3 loss per share $‍0.44​

* Intellia therapeutics announces third quarter 2017 financial results

Oct 31 2017

BRIEF-Intellia Therapeutics Q3 revenue $65 mln

* Intellia Therapeutics announces third quarter 2017 financial results

Oct 31 2017

BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China

* Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China

Jun 19 2017

Earnings vs. Estimates